RankAlpha logo
Back to Rankings

GOSS

Gossamer BioF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The September NDA plan, reacquired worldwide seralutinib rights and contingent financing could improve control, funding visibility and retained economics if regulatory execution progresses. [#PR-EARNINGS-2026-08-13]
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Additional financing may be required and could materially dilute shareholders.
Momentum
2
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.24 · Bull $0.60 · Bear $0.08Analysis 2026-09-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-06 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-10

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $1.66
Why
Momentum2 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.0.

Contradictions & invalidation

  • • Additional financing may be required and could materially dilute shareholders.
  • • Clinical-stage biotech valuation is highly sensitive to binary trial and regulatory outcomes.
  • • The Q2 adjusted loss was worse than cited consensus, cash remains limited for a clinical-stage company, financing may dilute shareholders, and the NDA and approval path remain binary.

Catalyst clock

2026-08-24

Financing and runway visibility

Lead driver: Value · See fundamentals
Momentum
2
9% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 1.6 / Value 41.2 / Sentiment 0.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-06. Scenario method

B+
Bull case
20%
Probability
Target price
$0.60
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$0.24
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.08
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$68.44M
Beta
1.94
Shares Out
488.85M
P/E (TTM) · Derived
-0.2
P/S (TTM)
14.40
P/FCF (TTM) · Derived
-0.21
Rev YoY
-19.6%
EPS YoY
-54.5%
Gross Margin
+98.3%
Op Margin
-297.7%
Net Debt
$65.97M
Current Ratio
0.53
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data